Atlastin 2 Inhibitor Mitigates Alzheimer's Mitochondrial Dysfunction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Alzheimer's disease focus on amyloid-beta and tau proteins, but these approaches have been largely ineffective, highlighting the need for a therapeutic agent targeting mitochondrial dysfunction, which is a major pathology in sporadic Alzheimer's disease.
Innovation Solution
A pharmaceutical composition comprising an inhibitor of Atlastin 2 (ATL2) expression or activity, which is elevated in Alzheimer's disease, to mitigate mitochondrial dysfunction, and a diagnostic method measuring ATL2 levels to diagnose and predict the disease.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments targeting amyloid-beta and tau proteins are used, then the disease pathology is addressed, but the treatments have been largely ineffective
Solution Approach 1:
Instead of continuing to target amyloid-beta and tau proteins (the conventional approach that has failed), the patent inverts the therapeutic strategy by targeting Atlastin 2, a protein involved in mitochondrial function and ER-mitochondria contact sites. This inversion of the therapeutic target represents a fundamental shift from targeting protein aggregates to targeting mitochondrial dysfunction, which has shown promise in treating Alzheimer's disease
Solution Approach 2:
The patent changes the therapeutic parameter from targeting amyloid-beta/tau proteins to targeting Atlastin 2 expression levels. By using inhibitors to reduce Atlastin 2 activity or expression, the treatment addresses mitochondrial dysfunction and oxidative stress, which are key pathological features of Alzheimer's disease that were not addressed by previous therapies
2Adaptability or versatility
If mitochondrial dysfunction is targeted as a therapeutic approach, then new treatment possibilities are opened, but the specific mechanism involving Atlastin 2 needs to be validated
Solution Approach 1:
The patent employs feedback mechanisms by using Atlastin 2 inhibitors and measuring their effect on mitochondrial function and Alzheimer's disease pathology. The therapeutic approach includes monitoring changes in mitochondrial health, oxidative stress levels, and disease markers to validate the mechanism and adjust treatment accordingly
Solution Approach 2:
Atlastin 2 serves as an intermediary target that connects ER-mitochondria contact sites to mitochondrial dysfunction. By inhibiting Atlastin 2, the treatment indirectly addresses mitochondrial health without directly targeting mitochondria, providing a mechanistic bridge between protein expression and functional outcomes
3Reliability
If Atlastin 2 inhibitors are used to treat Alzheimer's disease, then mitochondrial dysfunction is addressed, but the need for new drug development increases complexity
Solution Approach 1:
The patent develops Atlastin 2 inhibitors with potential multi-functionality, addressing not only mitochondrial dysfunction but also oxidative stress, ER stress, and neuroinflammation. This universal approach targets multiple pathological features of Alzheimer's disease through a single mechanism, potentially reducing the need for multiple separate therapies and simplifying treatment regimens
Data Source
AI summary
The present invention relates to a composition for preventing or treating Alzheimer’s disease, containing an inhibitor of ATL2, and a method of diagnosing the disease based on the measurement of the ATL2. In the present invention, it was found that PS1 mutants may result in mitochondrial dysfunction, such as increased binding between endoplasmic reticulum and mitochondria, increased mitochondrial ROS production, decreased mitochondrial membrane potential, decreased ATP production, decreased complex I activity, and decreased peroxidase activity, in brain glioma cells and that the PS1 mutants may abnormally increase the binding between endoplasmic reticulum and mitochondria by elevating the expression of the ATL2 in the brain. In addition, when the ATL2 was knocked down, it was observed that the binding between endoplasmic reticulum and mitochondria was lowered and that the expression of the ATL2 was elevated in the brains of Alzheimer’s disease animal models and patients. Accordingly, it is expected that it may possible to effectively prevent or treat Alzheimer’s disease by inhibiting the expression or activity of the ATL2 and that it may possible to diagnose the disease, predict the risk of developing the disease, and screen therapeutic agents for the disease, by measuring the level of the expression or activity of the ATL2.